Cancer patients with neutropenic septic shock: etiology and antimicrobial resistance

다국어 초록 (Multilingual Abstract)

Background/Aims: Among patients with febrile neutropenia that developed after chemotherapy, high-risk patients, such as those having clinical instability or Multinational Association of Supportive Care in Cancer score of < 21, require hospitalization for intravenous empiric antibiotic therapy. Monotherapy with an anti-pseudomonal ß-lactam agent is recommended. Although many studies reported the microbial etiology of infections and resistant patterns of febrile neutropenia, the patients were not well characterized as having neutropenic septic shock. Therefore, this study aimed to determine the microbial spectrum of infections and resistance patterns of their isolates in patients with chemotherapy-induced neutropenic septic shock.
Methods: Data of adult patients diagnosed with neutropenic septic shock in the emergency department between June 2012 and December 2016 were extracted from a prospectively compiled septic shock registry at a single academic medical center. Thereafter, microbiological studies and antimicrobial susceptibility tests were conducted.
Results: In total, 109 bacteria were found in patients with neutropenic septic shock. Gram-negative bacteria were the predominant causative organisms (84, 77.1%). Moreover, 33 microorganisms (30.3%) were multidrug-resistant (MDR) bacteria with extended-spectrum β-lactamase-producing Escherichia coli (17, 50%) being the commonest. The most commonly affected sites in patients with MDR bacterial infections were the gastrointestinal tract (45%) and unknown (43.5%).
Approximately 48.5% of MDR bacteria were resistant to cefepime but not to piperacillin- tazobactam or carbapenem.
Conclusions: MDR bacteria were prevalent in patients with chemotherapy-induced neutropenic septic shock. Therefore, piperacillin-tazobactam or carbapenem may be considered as empiric antibiotics if MDR bacteria are suspected to be causative agents.

참고문헌 (Reference)

1 Singer M, "The third international consensus definitions for sepsis and septic shock(Sepsis-3)" 315 : 801-810, 2016

2 Dellinger RP, "Surviving sepsis campaign : international guidelines for management of severe sepsis and septic shock : 2012" 41 : 580-637, 2013

3 Montassier E, "Recent changes in bacteremia in patients with cancer : a systematic review of epidemiology and antibiotic resistance" 32 : 841-850, 2013

4 Seo YB, "Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli" 17 : 404-, 2017

5 Wang L, "Prevalence of resistant gram-negative bacilli in bloodstream infection in febrile neutropenia patients undergoing hematopoietic stem cell transplantation: a single center retrospective cohort study" 94 : e1931-, 2015

6 Evans SE, "Pneumonia in the neutropenic cancer patient" 21 : 260-271, 2015

7 Kruse JM, "Neutropenic sepsis in the ICU : outcome predictors in a two-phase model and microbiology findings" 2016 : 8137850-, 2016

8 Magiorakos AP, "Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria : an international expert proposal for interim standard definitions for acquired resistance" 18 : 268-281, 2012

9 Penack O, "Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO)" 93 : 1083-1095, 2014

10 Sunder S, "Life-threatening Escherichia coli cellulitis in patients with haematological malignancies" 61 (61): 1324-1327, 2012

11 Barie PS, "Influence of antibiotic therapy on mortality of critical surgical illness caused or complicated by infection" 6 : 41-54, 2005

12 Chong CY, "Infections in acute lymphoblastic leukaemia" 27 : 491-495, 1998

13 Goethaert K, "Highdose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients" 12 : 56-62, 2006

14 이동건, "Evidence-Based Guidelines for Empirical Therapy of Neutropenic Fever in Korea" 대한내과학회 26 (26): 220-252, 2011

15 Kim SH, "Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever : factors associated with extended-spectrum β-lactamase production and its impact on outcome" 92 : 533-541, 2013

16 Bone RC, "Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine" 101 : 1644-1655, 1992

17 Trecarichi EM, "Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey" 21 : 337-343, 2015

18 Moet GJ, "Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe:report from the SENTRY Antimicrobial Surveillance Program (1998-2004)" 57 : 7-13, 2007

19 Freifeld AG, "Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer : 2010 update by the Infectious Diseases Society of America" 52 : 427-431, 2011

20 Zanetti G, "Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients : a multicenter, evaluator-blind, prospective, randomized study" 47 : 3442-3447, 2003

21 Lee NY, "Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae : MIC matters" 56 : 488-495, 2013

22 Levy MM, "2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference" 29 : 530-538, 2003